Drug Trial Radar · NCT07797231
Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
930
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Sep 2028
Study completion Oct 2029
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blind, placebo-controlled Phase III study with an open-label extension. The purpose is to evaluate efficacy and safety in adult patients with chronic hepatitis B virus infection who have received at least 12 months of NAs therapy, to demonstrate that TQA3605 Tablets combined with oral nucleos(t)ide analogues can improve efficacy with satisfactory safety profile compared with oral nucleos(t)ide analogues alone in this population. Approximately 930 adult patients with chronic hepatitis B virus infection who have received at least 12 months of NAs therapy are planned to be enrolled in this study.
Conditions
- Chronic Hepatitis B
Interventions
TQA3605 tablets PlaceboDrug
Placebo contains no active substance.
TQA3605 tabletsDrug
TQA3605 tablets are core protein allosteric modulators
Entecavir dispersible tabletsDrug
Entecavir dispersible tablets are a type of nucleoside analog antiviral drug.
Tenofovir Disoproxil Fumarate TabletsDrug
Tenofovir Disoproxil Fumarate (TDF) is a nucleoside reverse transcriptase inhibitor.
Tenofovir Alafenamide Fumarate TabletsDrug
Tenofovir Alafenamide Fumarate (TAF) is a nucleoside reverse transcriptase inhibitor.
Tenofovir Amibufenamide TabletsDrug
Tenofovir Amibufenamide (TMF) is a phosphoramidate prodrug of tenofovir and belongs to nucleos(t)ide reverse transcriptase inhibitors.
Primary outcomes
What the sponsor says the trial is designed to measure.
- HBV DNATime frame: 48 weeks
Locations
76 sites in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
The First Affiliated Hospital of Ustc(Anhui Provincial Hospital)
Hefei, Anhui, China
The First Affiliated Hospital of Wannan Medical College / Yijishan Hospital of Wannan Medical College
Wuhu, Anhui, China
Beijing Ditan Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Peking University First Hospital
Beijing, Beijing Municipality, China
Beijing Youan Hospital,Capital Medical University
Beijing, Beijing Municipality, China
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
The Southwest Hospital of Amu
Chongqing, Chongqing Municipality, China
Chongqing University Three Gorges Hospital
Chongqing, Chongqing Municipality, China
Mengchao Hepatobiliary Hospital of Fujian Medical University
Fuzhou, Fujian, China
Zhongshan Hospital, Xiamen University
Xiamen, Fujian, China
The First Hospital of Lanzhou University
Lanzhou, Gansu, China
Gansu Wuwei Tumour Hospital
Wuwei, Gansu, China
Nanhai District People's Hospital of Foshan
Foshan, Guangdong, China
The Third Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
The Fifth Affiliated Hospital of Sun Yat-sen University
Zhuhai, Guangdong, China
Liuzhou Worker's Hospital
Liuzhou, Guangxi, China
Guizhou Provincial People's Hospital
Guiyang, Guizhou, China
Affiliated Hospital of Zunyi Medical University
Zunyi, Guizhou, China
Hainan Provincial People's Hospital
Haikou, Hainan, China
Hebei Petro China Central Hospital
Langfang, Hebei, China
Shijiazhuang Fifth Hospital
Shijiazhuang, Hebei, China
The Fourth Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Harbin Medical University, The Second Affiliated Hospital
Harbin, Heilongjiang, China
Mudanjiang Kang'an Hospital
Mudanjiang, Heilongjiang, China
Anyang People's Hospital
Anyang, Henan, China
Luoyang Central Hospital(Luoyang Central Hospital Affiliated to Zhengzhou University)
Luoyang, Henan, China
Puyang People's Hospital
Puyang, Henan, China
The Sixth People's Hospital of Zhengzhou
Zhengzhou, Henan, China
The first affiliated hospital of Zhengzhou university
Zhengzhou, Henan, China
Jingzhou Central Hospital
Jingzhou, Hubei, China
Second Xiangya Hospital of Central South University
Changsha, Hunan, China
The First Affiliated Hospital Of University Of South China
Hengyang, Hunan, China
The General Hospital of Hunan University of Medicine
Huaihua, Hunan, China
Chifeng Hospital
Chifeng, Inner Mongolia, China
Jiangsu Province Hospital
Nanjing, Jiangsu, China
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
The Fifth People's Hospital of Suzhou
Suzhou, Jiangsu, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
Showing 40 of 76 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.